Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Aug 11;7(9):593–602. doi: 10.1002/psp4.12321

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Sensitivity analysis of the developed kidney model. The sensitivity analysis was conducted using a hypothetical neutral drug with permeability of 10 × 10⁻⁶ cm/s and plasma unbound fraction of 0.1 (unless stated otherwise). Panel (a) shows the effects of unbound fraction (0.1–1) inside the renal cell and blood‐to‐plasma ratio (0.5–5) on simulated renal clearance (CL_r). Panel (b) shows the effects of tubular volume (0.1–10‐fold) and renal cell volume (0.1–10‐fold) on simulated renal clearance. Panel (c) shows the effects of in vitro permeability (0.1–200 × 10⁻⁶ cm/s) and plasma unbound fraction (0.1–1) on simulated renal clearance. Panel (d) shows the effects of glomerular filtration rate (GFR; 15–120 mL/min) and tubular surface area (0.1–10‐fold) on simulated renal clearance.